Genetic evidence for an additional factor required for erythropoietin-induced signal transduction

被引:20
作者
Gaffen, SL
Lai, SY
Longmore, GD
Liu, KD
Goldsmith, MA
机构
[1] Gladstone Inst Virol & Immunol, San Francisco, CA 94141 USA
[2] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA 94143 USA
[3] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA
[4] Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO 63110 USA
关键词
D O I
10.1182/blood.V94.1.74.413k36_74_86
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Erythropoietin (EPO) and its receptor (EPOR) are required for the development of mature erythrocytes. After binding of ligand, the EPOR activates a variety of signaling pathways that ultimately control cellular proliferation, survival, and specific gene expression. Although erythroid progenitors appear to be the principal EPO-responsive cell type in vivo due to the restricted expression of the EPOR, many growth factor-dependent cell lines expressing the EPOR can respond to EPO by activating many or all of these pathways. In the present study, we have identified a cellular context (the interleukin-2 [IL-2]-dependent HT-2 line) in which the EPO stimulation of the EPOR fails to support cellular proliferation, STAT-5 induction, or MAPK activation, despite efficient phosphorylation of the EPOR and JAK2 and inhibition of apoptosis after withdrawal of IL-2. Interestingly, when we fused HT-2 cells expressing the EPOR with Ba/F3 cells in a complementation assay, the resulting hybridomas proliferated and potently activated STAT-5 and MAPK in response to EPO. These data indicate that an unidentified cellular factor is needed to mediate signaling by the EPOR. Moreover, Ba/F3 cells apparently express this factor(s) and somatic fusions can, therefore, confer EPO responsiveness to HT-2 cells that lack this factor. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:74 / 86
页数:13
相关论文
共 85 条
[1]   Bcl-2 rescues T lymphopoiesis in interleukin-7 receptor-deficient mice [J].
Akashi, K ;
Kondo, M ;
vonFreedenJeffry, U ;
Murray, R ;
Weissman, IL .
CELL, 1997, 89 (07) :1033-1041
[2]   Cytokine signaling: Cytokine-inducible signaling inhibitors [J].
Aman, NJ ;
Leonard, WJ .
CURRENT BIOLOGY, 1997, 7 (12) :R784-R788
[3]  
[Anonymous], TRANSCRIPTION FACTOR
[4]   Erythropoietin activates Raf1 by an Shc-independent pathway in CTLL-EPO-R cells [J].
Barber, DL ;
Corless, CN ;
Xia, K ;
Roberts, TM ;
DAndrea, AD .
BLOOD, 1997, 89 (01) :55-64
[5]   Heteromerization of the γc chain with the interleukin-9 receptor α subunit leads to STAT activation and prevention of apoptosis [J].
Bauer, JH ;
Liu, KD ;
You, Y ;
Lai, SY ;
Goldsmith, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (15) :9255-9260
[7]   BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH [J].
BOISE, LH ;
GONZALEZGARCIA, M ;
POSTEMA, CE ;
DING, LY ;
LINDSTEN, T ;
TURKA, LA ;
MAO, XH ;
NUNEZ, G ;
THOMPSON, CB .
CELL, 1993, 74 (04) :597-608
[8]   Erythropoietin-induced erythroid differentiation of the human erythroleukemia cell line TF-1 correlates with impaired STAT5 activation [J].
Chretien, S ;
Varlet, P ;
Verdier, F ;
Gobert, S ;
Cartron, JP ;
Gisselbrecht, S ;
Mayeux, P ;
Lacombe, C .
EMBO JOURNAL, 1996, 15 (16) :4174-4181
[9]   The interleukin-7 receptor alpha chain transmits distinct signals for proliferation and differentiation during B lymphopoiesis [J].
Corcoran, AE ;
Smart, FM ;
Cowling, RJ ;
Crompton, T ;
Owen, MJ ;
Venkitaraman, AR .
EMBO JOURNAL, 1996, 15 (08) :1924-1932
[10]  
Damen JE, 1996, EXP HEMATOL, V24, P1455